nach oben

Erschienen in:

21.11.2017 | Original Article

Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy

verfasst von: Mark Thalgott, Martina Kron, Johannes M. Brath, Donna P. Ankerst, Ian M. Thompson, Juergen E. Gschwend, Kathleen Herkommer

Erschienen in: World Journal of Urology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP).

Methods

Patients were evaluated in a prospectively-collected PC family database: The focus was on hereditary prostate cancer (HPC) defined by Johns Hopkins criteria and sporadic prostate cancer (SPC), rigorously defined by absence of prostate cancer in ≥ 2 brothers aged ≥ 60 years. Additionally, patients with first-degree (FPC) and non-first-degree PC (non-FPC) were assessed. Endpoints were biochemical recurrence-free survival (BRFS) and prostate cancer-specific survival (CSS). Finally, clinico-pathological characteristics were compared and multiple proportional hazards regression was used to identify prognostic factors.

Results

In total 11,654 patients were included (807 HPC, 2251 FPC, 8072 non-FPC and 524 SPC). Familial imposition (HPC/FPC) was associated with a younger age at diagnosis. Thus, HPC patients were diagnosed 2.9 years earlier than SPC patients with more locally advanced tumors (≥ pT3). With a median follow up of 6.2 years (range 0–31.5) BRFS was significantly different when stratified by FH. In pairwise analyses BRFS differed significantly for HPC compared to SPC (HR = 1.27). Consecutively FH was identified as prognostic factor for BRFS (p = 0.021) together with age, PSA, pathologic characteristics and adjuvant androgen deprivation. Analyses of CSS did not show a difference.

Conclusion

Patients with FH of PC are likely to be diagnosed earlier and present a higher proportion of locally advanced disease. In addition, men with FH are at higher risk of biochemical recurrence after surgery but reveal similar outcomes regarding prostate cancer-specific survival.

Hemminki K (2012) Familial risk and familial survival in prostate cancer. World J Urol 30(2):143–148CrossRefPubMed

Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol 65(1):124–137CrossRefPubMed

Carter B, Bova G, Beaty T et al (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150(3):797–802CrossRefPubMed

Grill S, Fallah M, Leach RJ et al (2015) Incorporation of detailed family history from the swedish family cancer database into the PCPT risk calculator. J Urol 193(2):460–465CrossRefPubMed

Karyadi DM, Zhao S, He Q et al (2015) Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families. Int J Cancer 136(9):2166–2171CrossRefPubMed

Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W (2014) Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. Prostate 74(14):1444–1451CrossRefPubMed

Herkommer K, Schmidt C, Gschwend J (2011) Ten years national research project “familial prostate cancer”: problems in identifying risk families. Urol A 50(7):813–820CrossRef

Heck MM, Kron M, Gschwend JE, Herkommer K (2012) Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer. Eur J Cancer 48(9):1312–1317CrossRefPubMed

Pakkanen S, Kujala PM, Ha N, Matikainen MP, Schleutker J, Tammela TL (2012) Clinical and histopathological characteristics of familial prostate cancer in Finland. BJU Int 109(4):557–563CrossRefPubMed

10.

Saarimäki L, Tammela TL, Määttänen L et al (2015) Family history in the finnish prostate cancer screening trial. Int J Cancer 136(9):2172–2177CrossRefPubMed

11.

Sacco E, Prayer-Galetti T, Pinto F et al (2005) Familial and hereditary prostate cancer by definition in an Italian surgical series: clinical features and outcome. Eur Urol 47(6):761–768CrossRefPubMed

12.

Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML (2006) Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol 176(3):1118–1121CrossRefPubMed

13.

Rouprêt M, Fromont G, Bitker M-O, Gattegno B, Vallancien G, Cussenot O (2006) Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology 67(5):1028–1032CrossRefPubMed

14.

Lee KL, Marotte JB, Ferrari MK, McNeal JE, Brooks JD, Presti JC Jr (2005) Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy. Urology 65(2):311–315CrossRefPubMed

15.

Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA (2006) Aggressiveness of familial prostate cancer. J Clin Oncol 24(21):3445–3450CrossRefPubMed

16.

Valeri A, Azzouzi R, Drelon E et al (2000) Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 45(1):66–71CrossRefPubMed

17.

Paiss T, Wörner S, Kurtz F et al (2003) Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families. Eur J Hum Genet 11(1):17–22CrossRefPubMed

18.

Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479CrossRefPubMed

19.

Liss MA, Chen H, Hemal S et al (2015) Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol 193(1):75–79CrossRefPubMed

20.

Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK (2014) Does family history of prostate cancer affect outcomes following radiotherapy? Radiother Oncol 110(2):229–234CrossRefPubMedPubMedCentral

21.

Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH (1997) Familial prostate cancer: a different disease? J Urol 158(6):2197–2201CrossRefPubMed

22.

Rodríguez C, Calle EE, Miracle-McMahill HL et al (1997) Family history and risk of fatal prostate cancer. Epidemiology 8(6):653–657CrossRefPubMed

23.

Reed A, Ankerst DP, Pollock BH, Thompson IM, Parekh DJ (2007) Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol 178(5):1929–1932CrossRefPubMed

24.

Norrish A, McRae C, Cohen R, Jackson R (1999) A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int 84(3):311–315CrossRefPubMed

25.

D’Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299(3):289–295PubMed

26.

Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–996CrossRefPubMedPubMedCentral

Titel: Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy
verfasst von: Mark Thalgott
Martina Kron
Johannes M. Brath
Donna P. Ankerst
Ian M. Thompson
Juergen E. Gschwend
Kathleen Herkommer
Publikationsdatum: 21.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 2/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-017-2122-5

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer

Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma

Development and validation of 3D printed virtual models for robot-assisted radical prostatectomy and partial nephrectomy: urologists’ and patients’ perception

In vivo assessment of a novel biodegradable ureteral stent

Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder